Advertisement
EyeGate Pharmaceuticals I... (EYEG)
EyeGate Pharmaceuticals Statistics
Share Statistics
EyeGate Pharmaceuticals has 757.49K shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 757.49K |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | 8.45% |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | 193 |
| FTD / Avg. Volume | 13.9% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is 17.54 and the forward PE ratio is null. EyeGate Pharmaceuticals's PEG ratio is 0.
| PE Ratio | 17.54 |
| Forward PE | n/a |
| PS Ratio | 8.46 |
| Forward PS | 47.7 |
| PB Ratio | 5.26 |
| P/FCF Ratio | 15.84 |
| PEG Ratio | 0 |
Enterprise Valuation
EyeGate Pharmaceuticals has an Enterprise Value (EV) of 131.77M.
| EV / Sales | 8.23 |
| EV / EBITDA | 0 |
| EV / EBIT | 15.4 |
| EV / FCF | 15.41 |
Financial Position
The company has a current ratio of 4.94, with a Debt / Equity ratio of 0.
| Current Ratio | 4.94 |
| Quick Ratio | 4.94 |
| Debt / Equity | 0 |
| Debt / EBITDA | - |
| Debt / FCF | 0.01 |
| Interest Coverage | -122.89 |
Financial Efficiency
Return on Equity is 29.99% and Return on Invested Capital is 11.79%.
| Return on Equity | 29.99% |
| Return on Assets | 21.17% |
| Return on Invested Capital | 11.79% |
| Revenue Per Employee | $1.14M |
| Profits Per Employee | $551.77K |
| Employee Count | 14 |
| Asset Turnover | 0.44 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -2.07M |
| Effective Tax Rate | -36.49% |
Stock Price Statistics
The stock price has increased by 1.06% in the last 52 weeks. The beta is 0.27, so EyeGate Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 0.27 |
| 52-Week Price Change | 1.06% |
| 50-Day Moving Average | 35.27 |
| 200-Day Moving Average | 35.8 |
| Relative Strength Index (RSI) | 56.03 |
| Average Volume (20 Days) | 1.39K |
Income Statement
In the last 12 months, EyeGate Pharmaceuticals had revenue of 16.02M and earned 7.72M in profits. Earnings per share was 1.99.
| Revenue | 16.02M |
| Gross Profit | 16.02M |
| Operating Income | 2.64M |
| Net Income | 7.72M |
| EBITDA | 0 |
| EBIT | 5.64M |
| Earnings Per Share (EPS) | 1.99 |
Balance Sheet
The company has 3.79M in cash and 57.17K in debt, giving a net cash position of 3.74M.
| Cash & Cash Equivalents | 3.79M |
| Total Debt | 57.17K |
| Net Cash | 3.74M |
| Retained Earnings | -143.38M |
| Total Assets | 38.51M |
| Working Capital | 28.12M |
Cash Flow
In the last 12 months, operating cash flow was 8.56M and capital expenditures -6.26K, giving a free cash flow of 8.55M.
| Operating Cash Flow | 8.56M |
| Capital Expenditures | -6.26K |
| Free Cash Flow | 8.55M |
| FCF Per Share | 2.21 |
Margins
Gross margin is 100%, with operating and profit margins of 16.45% and 48.22%.
| Gross Margin | 100% |
| Operating Margin | 16.45% |
| Pretax Margin | 35.33% |
| Profit Margin | 48.22% |
| EBITDA Margin | n/a |
| EBIT Margin | 16.45% |
| FCF Margin | 53.39% |
Dividends & Yields
EYEG pays an annual dividend of $2.26, which amounts to a dividend yield of 5.93%.
| Dividend Per Share | $2.26 |
| Dividend Yield | 5.93% |
| Dividend Growth (YoY) | -4.54% |
| Payout Ratio | -127.92% |
| Earnings Yield | 5.7% |
| FCF Yield | 6.31% |
Analyst Forecast
Currently there are no analyst rating for EYEG.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Aug 30, 2019. It was a backward split with a ratio of 1:15.
| Last Split Date | Aug 30, 2019 |
| Split Type | backward |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | -3.27 |
| Piotroski F-Score | 4 |